9/17/2015 DIAGNOSTIC PUZZLES LEARNING OBJECTIVES MENTAL ILLNESS MEDICAL COMORBIDITIES
|
|
- Shona Thomas
- 5 years ago
- Views:
Transcription
1 DIAGNOSTIC PUZZLES MENTAL ILLNESS MEDICAL COMORBIDITES SUBSTANCE ABUSE SPECIAL POPULATIONS IMPROVING COMPLIANCE CASE STUDIES LEARNING OBJECTIVES Learner will be able to identify substance abuse and state 3 medications safe to use for depression, anxiety and insomnia in persons with a substance abuse history. Learner will be able to differentiate between depression and dementia in the elderly and use of medications in this population Learner will be able to state 3 strategies for improving treatment compliance MEDICAL COMORBIDITIES Many medical problems mimic or exacerbate psychiatric symptoms Many medications can have side effects of depression Medications metabolized by Cytochrome P pathways can interact with most psychotropic medications, and drug interactions should always be checked before making any medication changes. There is a high incidence of depression and/or anxiety with many chronic illnesses; heart disease, diabetes, chronic pain 1
2 ASSOCIATION OF COMORBIDITIES Current Depression and Lifetime Diagnosis of Depression and Anxiety by Asthma, Diabetes, and CVD Status Status Current Depression (%) Lifetime Diagnosis of Depression (%) Lifetime Diagnosis of Anxiety (%) Asthma No asthma CVD No CVD Diabetes No diabetes DEPRESSION, SUBSTANCE ABUSE & SUICIDE Over 60 percent of all people who die by suicide suffer from major depression. If one includes alcoholics who are depressed, this figure rises to over 75 percent. Depression affects nearly 10 percent of Americans ages 18 and over in a given year, or more than 24 million people. More Americans suffer from depression than coronary heart disease (17 million), cancer (12 million) and HIV/AIDS (1 million). According to reports published in the Journal of the American Medical Association: Roughly 50 percent of individuals with severe mental disorders are affected by substance abuse. 37 percent of alcohol abusers and 53 percent of drug abusers also have at least one serious mental illness. Of all people diagnosed as mentally ill, 29 percent abuse either alcohol or drugs. SUICIDE RISKS Alcohol and Suicide: Ninety-six percent of alcoholics who die by suicide continue their substance abuse up to the end of their lives. Alcoholism is a factor in about 30 percent of all completed suicides. Approximately 7 percent of those with alcohol dependence will die by suicide. Firearms and Suicide: Although most gun owners reportedly keep a firearm in their home for "protection" or "self defense," 83 percent of gun-related deaths in these homes are the result of a suicide, often by someone other than the gun owner. Firearms are used in more suicides than homicides. Death by firearms is the fastest growing method of suicide. Firearms account for 50 percent of all suicides. Medical Illness and Suicide: Patients who desire an early death during a serious or terminal illness are usually suffering from a treatable depressive condition. People with AIDS have a suicide risk up to 20 times that of the general population. Studies indicate that the best way to prevent suicide is through the early recognition and treatment of depression and other psychiatric illnesses. 2
3 OREGON SUICIDE RATES Compared to the national average, Oregon suicide rates have been higher for the past three decades. The most recently available national data shows Oregon age-adjusted suicide rate of 17.1 per 100,000 in 2010 was 41 percent higher than the national average Oregon ranked 9th place among all US states in suicide incidence. Between 2003 and 2010, Oregon suicide rates were significantly higher than the national average among all age groups except ages and women ages ADDRESSING SUBSTANCE AND ALCOHOL USE PRIOR TO TREATMENT Substance abuse is defined as a pattern of harmful use of any substance for mood-altering purposes. Mental illness refers to disorders generally characterized by dysregulation of mood, thought, or behavior (as recognized by the Diagnostic and Statistical Manual, 5th edition, of the American Psychiatric Association (DSM-5). Dealing with either can be difficult, but it is often more difficult to deal with both. Each disorder has its own unique symptoms that can impair one s ability to function and often interact with each other. IDENTIFYING SUBSTANCE ABUSE CAGE Questions 1. Have you ever felt you should cut down on your drinking? 2. Have people annoyed you by criticizing your drinking? 3. Have you ever felt bad or guilty about your drinking? 4. Have you ever had a drink first thing in the morning to steady your nerves or to get rid of a hangover (eye-opener)? CAGE Questions Adapted to Include Drug Use (CAGE-AID) 1. Have you ever felt you ought to cut down on your drinking or drug use? 2. Have people annoyed you by criticizing your drinking or drug use? 3. Have you felt bad or guilty about your drinking or drug use? 4. Have you ever had a drink or used drugs first thing in the morning to steady your nerves or to get rid of a hangover (eye-opener)? 3
4 WHY DO SOME DRUG USERS BECOME ADDICTED, WHILE OTHERS DON T? Risk factors that increase your vulnerability include: Family history of addiction Abuse, neglect, or other traumatic experiences in childhood Mental disorders such as depression and anxiety Early use of drugs Method of administration smoking or injecting a drug may increase its addictive potential WHEN CAN YOU GIVE A NARCOTIC TO SOMEONE WITH A HISTORY OF SUBSTANCE ABUSE? ADHD? Anxiety? Insomnia? Chronic pain? DEPRESSION IN PRIMARY CARE 4
5 TYPES OF TREATMENT ANTIDEPRESSANT MEDICATIONS PSYCHOTHERAPY LIGHT THERAPY, ECT, ALTERNATIVE THERAPIES SSRI S FIRSTLINETREATMENT FOR DEPRESSION AND ANXIETY Fluoxetine (Prozac) Fluvoxamine (Luvox) Sertraline (Zoloft) Paroxetine (Paxil) Escitalopram (Lexapro) Citalopram (Celexa) ATYPICAL ANTIDEPRESSANT GENERIC AND BRAND NAMES Bupropion (Wellbutrin) Duloxetine (Cymbalta) Venlafaxine (Effexor) Mirtazapine (Remeron) Trazodone (Desyrel) 5
6 TRICYCLIC ANTIDEPRESSANTS GENERIC AND BRAND NAMES Amitriptyline (Elavil) Clomipramine (Anafranil) Desipramine (Norpramin) Doxepin (Sinequan) Imipramine (Tofranil) Nortriptyline (Pamelor, Aventyl) Protriptyline (Vivactil) Trimipramine (Surmontil ) MAOI GENERIC AND BRAND NAMES Phenelzine (Nardil) Tranylcypromine (Parnate) Isocarboxazid (Marplan) Selegiline (Emsam) ALTERNATIVE TREATMENTS Herbal remedies; St. Johns Wort, Ginko, Kava to name a few. These may interfer with other medications. Supplements; Vitamins, especially B12, Omega 3 Fatty acids Music, pet therapy, massage, dance and acupuncture. 6
7 DEPRESSION TREATMENT-RISKS Antidepressants can increase suicidal thoughts and behaviors in children, teens, and young adults. (Black Box Warning) Be especially observant within the first few months of treatment or after a change in dose. Over 36,000 people in the United States die by suicide every year, Suicide is the fourth leading cause of death for adults between the ages of 18 and 65 years in the United States. Currently, suicide is the 10th leading cause of death in the United States (2009). INSOMNIA Insomnia is one of the leading symptoms accompanying a variety of somatic and mental health problems. Approximately one-third of Americans experience difficulty sleeping, and in primary care patients the number may be as high as 2/3 of the patients seen. TREATMENTS Medications Alternative/Natural Sleep Remedies Sleep Hygiene Behavioral Techniques 7
8 SLEEP TIPS 1. Establish a Regular Routine: 2. Get an Adequate Amount of Sleep Every Night 3. Go to Bed When You Are Sleepy: 4. Develop Sleep Rituals Before Going to Bed: 5. Avoid Stress and Worries at Bedtime: 6. Use Your Bed for Sleeping and Sex Only: 7. Avoid Heavy Meals Late in the Evening: 8. Reduce Your Intake of Caffeine and Nicotine: 9. Avoid Alcohol 4-6 Hours Before Bedtime: 10. Exercise regularly: 11. Don't nap for more than 30 minutes or after 3 p.m: 12. Keep it Dark and Cool: 13. Use Sleeping Aids Conservatively:. SEDATIVES/HYPNOTICS Flurazepam-Dalmane Temazepam-Restoril Triazolam-Halcion Zolpidem-Ambien Zaleplon-Sonata Lunesta Rozerem (non-narcotic) safe in the elderly SEDATING ANTIDEPRESSANTS Tricyclics-Amitriptyline, Nortriptyline (not FDA approved) Silenor-(Doxepin) 3mg & 6mg FDA approved for insomnia adults, and geriatrics Trazodone-Deseryl-(off label) Mirtazepine-Remeron (off-label) 8
9 OTHERS Antipsychotics-Quetiapine Antihistamines-hydroxyzine, diphenhydramine Antianxiety-lorazepam, diazepam, alprazolam, clonazepam, ect ALTERNATIVE THERAPIES L-Trytophan Melatonin Valerian root Herbal Teas- chamomile ANXIETY Benzodiazepines; use or not use? Benzodiazepines are effective in the treatment of anxiety, especially in panic disorder but have high risk of tolerance, dependence and abuse 9
10 BENZODIAZEPINES Intermediate Acting- alprazolam, lorazepam, Long Acting- chlordiazepoxide, clonazepam, diazepam, clorazepate ALTERNATIVE TREATMENTS Buspirone FDA Approved for anxiety, non narcotic, most helpful in patients with medical comorbidities, poor tolerance to medications, and in geriatrics. Hydroxyzine Pamoate- can be helpful as a prn but can be very sedating for some, and has significant anticholinergic effects Antidepressants-SSRI s, SNRI s, Trazodone, Mirtazapine Atypical s- Seroquel, zyprexa, very sedating and risk of metabolic syndrome, but can be very effective in small doses. WHAT IS OFF-LABEL PRESCRIBING? Off-label is the use of a drug outside the terms of its license Prescribing a dose in excess of that specified by the FDA Prescribing for an unlicensed indication Prescribing for a patient group outside of that specified by the FDA, such as children or the elderly 10
11 DEPRESSION IN THE ELDERLY Depression and dementia share many of the same symptoms. This can make it difficult to identify depression in people with dementia. Recognition and treatment of depression has the potential to improve functioning and quality of life in spite of the presence of other medical comorbidities. Also they often present with somatic complaints, or non-adherence to treatment versus complaints of depression Increase risk of suicide SCREENING TOOL ELDERLY PRESCRIBING Usually need much lower doses, and can become toxic over time especially with benzodiazepines, and become delirious. Impaired kidney or hepatic function need to decrease dose of most medications, (some psych meds can cause liver or kidney problems) Antipsychotics have black-box warnings in elderly. Increased risk for drug-drug interactions secondary to complex medication regimes for medical co-morbidities 11
12 ANTIDEPRESSANTS IN THE ELDERLY Usually start with lower doses Choose ones with best side effect profiles Avoid tricyclics if possible Watch for drug-drug interactions DEPRESSION, DELIRIUM, DEMENTIA? In order to make a diagnosis of dementia, delirium must be ruled out. However, patients with dementia are at increased risk of delirium and may have both. Delirium is an acute disorder of attention and global cognition (memory and perception) and is treatable. The diagnosis is missed in more than 50% of cases. Clients with dementia can also have depression DEPRESSION VERSUS DEMENTIA In depression, even when severe, other impairments typical of dementia (such as in speech, powers of reasoning and ability to orientate themselves in time and space) are unusual. In contrast, in a person with dementia these abilities are likely to be impaired. A depressed person will occasionally complain of an inability to remember things but will remember when prompted, whereas a person with dementia will be forgetful and will often try to cover up memory lapses. In severe depression, the powers of reasoning and memory may be very badly impaired, and it is this state that is most easily confused with dementia. This impairment is mainly due to poor concentration, and the condition is reversible with treatment or when the depression lifts. This is not the case with dementia. 12
13 DELIRIUM VERSUS DEMENTIA Acute onset Acute illness Disorientation Early Variable moment to moment Short Attention span Disturbed sleep-wake cycle Tactile hallucinations most common, may have visual also Gradual onset Chronic illness Disorientation Late Generally stable Attention reduced Sundowner s syndrome Hallucinations later and more likely visual DELIRIUM PREVENTION Avoidance of psychoactive drugs, medication assistance as to prevent incorrect dosing of medications; structured daytime activity, dark and quiet at night (for good sleep), visual and hearing assistive devices, orientation devices PSYCHOSIS AND DEMENTIA Although some atypical antipsychotic medications are modestly helpful for some patients, they are not effective for the majority of Alzheimer's patients with psychotic symptoms. Good clinical practice requires that medical or environmental causes for Alzheimer's-related agitation and aggression be ruled out and that behavioral interventions be considered before turning to antipsychotic medications. If an antipsychotic medication then is warranted, clinicians should closely monitor their Alzheimer's patients for intolerable side effects and potential safety concerns 13
14 TREATMENT OF NON-EMERGENT AGITATION IN DEMENTIA Start treatment with a cholinesterase inhibitor. Add memantine if the patient is moderate to severely demented. If agitation persists, try an SSRI antidepressant. If the SSRI antidepressant is unhelpful, trial trazodone. If these strategies are unhelpful, try either risperidone or aripiprazole. If both trials fail, use quetiapine. If quetiapine trial fails, use olanzapine. If olanzapine trial fails, use either divalproex or carbamazepine. If all the monotherapy trials fail, only then use combination therapy.* Avoid benzodiazepines! STRATEGIES TO ENHANCE PATIENT ADHERENCE Studies have shown that in the United States alone, non-adherence to medications causes 125,000 deaths annually and accounts for 10% to 25% of hospital and nursing home admissions. This makes non-adherence to medications one of the largest and most expensive disease categories. Moreover, patient non-adherence is not limited to medications alone. It can also take many other forms; these include the failure to keep appointments, to follow recommended dietary or other lifestyle changes, and to follow other aspects of treatment or recommended preventive health practice KEEP IT SIMPLE - SIMPLIFYING REGIMEN CHARACTERISTICS 1. Adjusting timing, frequency, amount, and dosage 2. Matching to patients' activities of daily living 3.Using adherence aids, such as medication boxes and alarm 14
15 IMPARTING KNOWLEDGE: Discussion with physician, nurse, or pharmacist Distribution of written information or pamphlets Accessing health-education information on the Web MODIFYING PATIENT BELIEFS: Assessing perceived susceptibility, severity, benefit, and barriers Rewarding, tailoring, and contingency contracting PATIENT AND FAMILY COMMUNICATION Active listening and providing clear, direct messages Including patients in decisions Sending reminders via mail, , or telephone Convenience of care, scheduled appointments Home visits, family support, counseling 15
16 LEAVING THE BIAS Tailoring the education to patients' level of understanding EVALUATING ADHERENCE Self-reports (most commonly used) Some possible questions- 1.Do you ever forget to take your medications? 2.Are you careless at times about taking medications? 3.When you feel better, do you sometimes stop taking medications? 4.Sometimes, when you feel worse, do you stop taking your medicine? Pill counting, measuring serum or urine drug levels CASE STUDY #1 45 yo hispanic female with CHF, Diabetes II, morbid obesity presents with complaints of severe anxiety, and insomnia Medications: O2 continuously 2lpm; spirolactone 50mg daily, seroquel 100mg TID, amitriptyline 200mg QHS, enalapril 20mg ii dily, metformin 500mg daily, celexa 40mg daily, valium 5mg TID, ultram i-ii q4-6h prn pain, albuteral inhaler prn What would you do? 16
17 CASE STUDY #2 35 yo married caucasian male presents with history of episodes of anxiety with paranoia multiple stressors, unable to hold a job, moves frequently, alcohol abuse, currently presents as depressed with low energy, fatigue, low energy, nightmares of physical abuse as a child; drinks 2-3 beers or whiskey every night. Current Medications: Bupropion XL 300mg, lorazepam 1mg prn anxiety Diagnosis? Medication changes? REFERENCES Texas Medication algorithm project(tmap) NIMH website: Innovations in clinical neuroscience on-line at: Facts and Figures/National Statistics: iewpage&page_id=050fea9f-b b1135c3a70de1fda ADDITIONAL REFERENCES Current Psychiatry free journal also available on-line Texas Medication algorithm project(tmap) and others NIMH website: Innovations in clinical neuroscience on-line at: Clinical Handbook of psychotropic drugs 19 th ed. Clinical Handbook of psychotropic drugs for children and adolescents by Normand J. Carrey, Barry A. Martin, Aidan Stokes, and Umesh Jain 17
18 REFERENCES CONTINUED Differentiating between Depression & Dementia Dementia Today June 17,2015: Depression and Comorbid Illness in Elderly Primary Care Patients: Impact on Multiple Domains of Health Status and Well-Being Polly Hitchcock Noël, PhD; John W. Williams, Jr, MD, MHS; Jürgen Unützer, MD, MPH; Jason Worchel, MD; Shuko Lee, MS; John Cornell, PhD; Wayne Katon, MD; Linda H. Harpole, MD, MPH; Enid Hunkeler, MA Ann Fam Med. 2004;2(6) SUBSTANCE Abuse and mental illness: Strategies to Enhance Patient Adherence: Making it Simple Ashish Atreja, MD, MPH, Fellow, Naresh Bellam, MD, MPH, Resident Physician, and Susan R. Levy, PhD, Professor Emeritus 18
PSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationMental Health Intake Form
Current Symptoms Checklist: (check once for any symptoms present, twice for major symptoms) ( ) ( ) Depressed mood ( ) ( ) Racing thoughts ( ) ( ) Excessive worry ( ) ( ) Unable to enjoy activities ( )
More informationRichard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationDuragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
More informationThe Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State
The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State RAI/MDS Coordinator Objectives Upon completion of this training,
More informationPsychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA
Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get
More informationHappy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?
Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms
More informationMental Health Intake Form
38600 Van Dyke Ave., Suite 200 Sterling Heights, MI 48313 Phone: (586) 933-5395 Fax: (586) 935-0159 Mental Health Intake Form Please complete all information on this form and bring it to the first visit.
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationOverview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials
SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the
More informationUSF Health Psychiatry Clinic. New Patient Questionnaire Adult
USF Health Psychiatry Clinic New Patient Questionnaire Adult Please mail or fax the completed forms to the address/fax number on the bottom of this page. Completed forms must be received five (5) days
More informationNew Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationMajor Depressive Disorder
Major Depressive Disorder HEDIS Measures And Clinical Practice Guidelines Jennifer Highley, PMHNP-BC Behavioral Health West Point Healthcare Effectiveness Data and Information Set (HEDIS) Performance measures
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationInsomnia: Updates in Medical Management. Michael Newnam M.D.
Insomnia: Updates in Medical Management Michael Newnam M.D. Sleep Neurobiology Delicate balance of excitatory and inhibitory neurotransmitters that control the switch between wakefulness and sleep Circadian
More informationMO Medicaid Foster Care Drugs FY10-FY14
MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationXartemis XR (oxycodone / acetaminophen extended release)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 9 Last Review Date: September 15, 2017 Duragesic patch Description Duragesic patch (fentanyl
More informationBELBUCA (buprenorphine buccal film)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Section: Prescription Drugs Effective Date: April1, 2017 Subject: Duragesic patch Page: 1 of 10 Last Review Date: March
More informationButrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description
More informationDual Diagnosis: Substance Abuse and Mental Illness
Dual Diagnosis: Substance Abuse and Mental Illness and a review of the major PSYCHIATRIC MEDICINES Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
More informationBelbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2017 Belbuca (buprenorphine buccal film)
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 8 Last Review Date: September 15, 2017 Embeda Description Embeda (morphine
More informationDealing with a Mental Health Crisis
Dealing with a Mental Health Crisis Information and Resources for First Responders P... PROFESSIONAL WHAT NAMI DOES NAMI Minnesota is a statewide 501(c)(3) grassroots nonprofit organization dedicated to
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationDepression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms
Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)
More informationBelbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2016 Belbuca (buprenorphine buccal film)
More informationSteps for Initiating Electroconvulsive Therapy Treatment
Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationBefore you try another medication, try asking your DNA
Before you try another medication, try asking your DNA It s not you, it s your genetics If you re having trouble finding a medication that works for you, don t give up hope. Here s the thing we all respond
More informationHysingla ER. Hysingla ER (hydrocodone bitartrate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.38 Subject: Hysingla ER Page: 1 of 9 Last Review Date: September 15, 2017 Hysingla ER Description
More informationUPDATE ON THE OUTPATIENT TREATMENT OF PSYCHIATRIC DISORDERS Amanda J. Williams, MD Grayson & Associates Montgomery, AL
UPDATE ON THE OUTPATIENT TREATMENT OF PSYCHIATRIC DISORDERS Amanda J. Williams, MD Grayson & Associates Montgomery, AL Objectives Differentiate the multiple causes of depressed mood and anxiety, and identify
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationNucynta IR. Nucynta IR (tapentadol immediate-release) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta IR Page: 1 of 9 Last Review Date: December 8, 2017 Nucynta IR Description Nucynta IR (tapentadol
More informationDepression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.
Depression Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious,
More informationAn algorithm for medication in the treatment of Complex PTSD
An algorithm for medication in the treatment of Complex PTSD Andreas Laddis, M.D. aladdis@gmail.com ESTD Conference Bern November 10, 2017 The purpose for the presentation Algorithm for medication: My
More informationUnderstanding Alzheimer s Disease
Understanding Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disorder that slowly impacts memory, thinking, skills and, eventually, the ability to carry out the simplest
More informationMedications Guide: Public Speaking And Social Anxiety
AnxietyHub.org Dr. Cheryl Mathews Medications Guide: Public Speaking And Social Anxiety Copyright 2016 AnxietyHub Medications Specifically for Public Speaking and Social Anxiety This is not intended to
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Duragesic patch Page: 1 of 9 Last Review Date: November 30, 2018 Duragesic patch Description Duragesic patch (fentanyl
More informationInsomnia % of adults suffer from chronic and severe insomnia (Complaints of insomnia with daytime consequences)
10-15% of adults suffer from chronic and severe insomnia (Complaints of insomnia with daytime consequences) 30 40% of adults complain of insomnia symptoms only 95% experience insomnia at some time in their
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Meperidine Page: 1 of 7 Last Review Date: September 15, 2017 Meperidine Description Demerol (meperidine
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationPharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests
Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationShort Clinical Guidelines: General Anxiety Disorder (GAD)
Definition is one of the most prevalent psychiatric disorders seen in the primary care office and is characterized by excessive anxiety and worry about a number of events that cause clinically significant
More informationPsychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN
Psychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN Psycho-Oncology Consultants, LLC & The University of Cincinnati Central Clinic University of Cincinnati Central Clinic www.centralclinic.org
More informationMental Health Medications. National Institute of Mental Health. U.S. Department of HealtH and HUman ServiceS National Institutes of Health
Mental Health Medications National Institute of Mental Health U.S. Department of HealtH and HUman ServiceS National Institutes of Health Contents Mental Health Medications...1 What are psychiatric medications?...1
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationDEPRESSION. Men and women of all ages, races, and economic levels can have depression. It occurs more often in women.
DEPRESSION The exact cause of depression is not known. Many researchers believe it is caused by chemical imbalances in the brain, which may be hereditary or caused by events in a person's life. Some types
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately severe chronic pain in adults. Along from analgesia, tramadol
More informationPrimary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017
John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately
More informationMorphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationAnti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.
30-3-2007 Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of. 30-3-2018 C. Psychiatric drugs: controlled trial demonstrated
More informationChange Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness
Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.
More informationOxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 11 Last Review Date: March 17, 2017 Oxycodone Description Oxycodone IR, Oxycodone
More informationOxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 10 Last Review Date: September 15, 2016 Oxycodone Description Oxycodone IR,
More informationObjectives: Lifetime prevalence. Neurotransmitters of interest
Kelly Kll M. Rock, DNP, CRNP 11/5/11 Objectives: Identify lifetime prevalence of depressive and anxious disorders. Recognize the social and economic burden of depressive and anxious disorders. Understand
More informationTarginiq ER (oxycodone/naloxone extended-release), Troxyca ER (oxycodone /naltrexone extended-release)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.44 Subject: Oxycodone Naloxone Page: 1 of 9 Last Review Date: December 2, 2016 Oxycodone Naloxone
More informationSUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,
More informationToo Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities
Too Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities One definition of polypharmacy is using more medications than is medically necessary. However, it can be
More informationPATIENT FACE SHEET PATIENT NAME: PATIENT DOB: PATIENT PHONE #: INSURANCE: MEMBER ID: GROUP NUMBER: PATIENT ADDRESS
1 P a g e PATIENT FACE SHEET PATIENT NAME: PATIENT DOB: PATIENT PHONE #: INSURANCE: MEMBER ID: GROUP NUMBER: PATIENT ADDRESS PRIOR AUTHORIZATION #: (for office use only) INS. CONTACT NAME/ DIRECT NUMBER:
More informationAdult Initial Assessment / Patient Questionnaire Page 1
Page 1 Patient Name: Date: Age: Date of Birth: / / Please read the following questions and answer to the best of your ability by placing a checkmark in the appropriate boxes or filling in the blank as
More informationU T I L I Z A T I O N E D I T S
I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental
More informationDisclosure. Objective 1. Objective 2. Naval Health Center New England. Objective 3. APNA 27th Annual Conference Session 1036: October 9, 2013
Understanding Sleep and Antidepressants: Lessons from Research Literature and Clinical Practice Joseph M. Holshoe, PMHNP-BC Commander, U.S. Public Health Service Behavioral Health Consultant, Primary Care
More informationTreatment of Major Depressive Disorder
Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation
More information2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources
Drugs and Dementia in the Hospice Patient Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources 1 Drug Therapy: Targeted at Symptoms Cognitive: Impaired abstract thinking Impaired
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationMental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Mood Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Mood Prolonged emotional state that influences the person s whole personality and life functioning Adaptive Functions
More informationPsychiatric Treatment of the Concussed Athlete
Psychiatric Treatment of the Concussed Athlete Eastern Athletic Trainers Association January 11 th, 2015 Alexander S. Strauss, MD Centra, P.C. E-MAIL: DRSTRAUSS@ALEXSTRAUSSMD.COM Evidence Mounts Linking
More informationTREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD
TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background hydromorphone (Exalgo, Dilaudid) and oxymorphone (Opana and Opana ER) are Schedule II narcotics prescribed to treat moderate to severe pain. Morphine produces
More informationTreatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers
Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers By Kelsey F. Lee, PharmD candidate 2011 Preceptor: Demetra Antimisiaris, PharmD University of Louisvlle Dept. Family Medicine
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More information